These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease. Monfredi O; Griffiths L; Clarke B; Mahadevan VS Am J Cardiol; 2011 Nov; 108(10):1483-8. PubMed ID: 21943933 [TBL] [Abstract][Full Text] [Related]
32. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Sitbon O; Badesch DB; Channick RN; Frost A; Robbins IM; Simonneau G; Tapson VF; Rubin LJ Chest; 2003 Jul; 124(1):247-54. PubMed ID: 12853530 [TBL] [Abstract][Full Text] [Related]
33. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ; J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129 [TBL] [Abstract][Full Text] [Related]
34. Effect of Bosentan on Claudication Distance and Endothelium-Dependent Vasodilation in Hispanic Patients With Peripheral Arterial Disease. De Haro J; Bleda S; Varela C; Esparza L; Acin F; Am J Cardiol; 2016 Jan; 117(2):295-301. PubMed ID: 26651453 [TBL] [Abstract][Full Text] [Related]
35. Bosentan for the treatment of pulmonary arterial hypertension. Kenyon KW; Nappi JM Ann Pharmacother; 2003; 37(7-8):1055-62. PubMed ID: 12841819 [TBL] [Abstract][Full Text] [Related]
36. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. Galiè N; Hinderliter AL; Torbicki A; Fourme T; Simonneau G; Pulido T; Espinola-Zavaleta N; Rocchi G; Manes A; Frantz R; Kurzyna M; Nagueh SF; Barst R; Channick R; Dujardin K; Kronenberg A; Leconte I; Rainisio M; Rubin L J Am Coll Cardiol; 2003 Apr; 41(8):1380-6. PubMed ID: 12706935 [TBL] [Abstract][Full Text] [Related]
37. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). Teerlink JR; Löffler BM; Hess P; Maire JP; Clozel M; Clozel JP Circulation; 1994 Nov; 90(5):2510-8. PubMed ID: 7955209 [TBL] [Abstract][Full Text] [Related]
38. Initial experience with bosentan therapy in patients considered ineligible for heart transplantation because of severe pulmonary hypertension. Perez-Villa F; Cuppoletti A; Rossel V; Vallejos I; Roig E Clin Transplant; 2006; 20(2):239-44. PubMed ID: 16640533 [TBL] [Abstract][Full Text] [Related]
39. Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensin-converting enzyme inhibition. Donckier JE; Massart PE; Hodeige D; Van Mechelen H; Clozel JP; Laloux O; Ketelslegers JM; Charlier AA; Heyndrickx GR Circulation; 1997 Aug; 96(4):1250-6. PubMed ID: 9286956 [TBL] [Abstract][Full Text] [Related]
40. Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis-an interim analysis of results from a prospective, single-center, randomized, parallel-group study. Tanaka Y; Hino M; Gemma A BMC Pulm Med; 2017 Dec; 17(1):200. PubMed ID: 29237441 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]